

MedCap AB (publ) has signed an agreement to acquire Biopsafe ApS in Denmark.

Biopsafe provides an innovative container for safer handling in biopsy procedures. The company's revenue amount to approximately 50 MDKK with good profitability and sales on several European markets.

Biopsafe will be part of MedCap's business area MedTech.

"Biopsafe has an innovative product and has established a leading position in its niche on several European markets. The company makes a nice addition to the business area Medtech and we look forward to continuing the development together with the team.", comments Anders Dahlberg, CEO MedCap.

The acquisition is made at a cash purchase price of 115 MDKK adjusted for cash and net debt at closing which occurred on June 26th.

For more information, contact:

Anders Dahlberg, CEO, mobile +46 704 26 92 62, e-mail anders.dahlberg@medcap.se

About MedCap

MedCap builds successful life sciences companies to improve people's lives. MedCap unites the strengths of a larger the company with the smaller companies' entrepreneurial power, agility, and business acumen. MedCap is publicly listed on NASDAQ Stockholm OMX, with the symbol MCAP. More information is available on the company web site www.medcap.se.

This information is information that MedCap is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-06-26 15:40 CEST.